Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type abstract
PMID
Authors Victor M. Rivera, Wei-Sheng Huang, Mengrou Lu, Justin R. Pritchard, David Dalgarno, William C. Shakespeare
Title Abstract 1292: Preclinical characterization of THE-630, a next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST)
Journal Cancer Res
Vol 81
Issue 13 Suppl
Date 2021
URL https://cancerres.aacrjournals.org/content/81/13_Supplement/1292
Abstract Text Introduction: GIST is the most common sarcoma of the GI tract, with most cases driven by activating mutations in KIT Ex11 or Ex9. Prognosis is poor for patients whose tumors progress following first-line (1L) imatinib treatment, despite availability of 3 approved drugs (sunitinib [2L], regorafenib [3L], ripretinib [4L]). In most patients, resistance is driven by secondary mutations in KIT, with nearly all occurring in either the ATP binding pocket (Ex13/14) or activation loop (Ex17/18). No approved drug has potent activity against both classes of resistance mutations and most patients appear to have multiple resistance mutations. There remains a need for a pan-mutant KIT inhibitor, which has potent activity against all classes of mutations. Experimental Procedures: Drug activity was determined by assessing effects on tumor cell lines and BaF3 cells expressing mutant forms of KIT. Mice were dosed orally once (THE-630 and sunitinib) or twice (ripretinib) daily at doses that did not exceed the MTD. Results: THE-630 potently (IC50 ~3 nM) inhibited KIT-driven viability and downstream signaling in GIST-T1 cells, which contain an activating deletion in Ex11 (Ex11Del). Similar results were observed in engineered BaF3 cells containing Ex11Del or an activating insertion in Ex9 (both IC50s ≤3 nM), whereas potency of imatinib, regorafenib, and ripretinib, was reduced by ≥5-fold against the Ex9 variant. Consistent with available clinical data, in engineered BaF3 cells containing a primary Ex11Del mutation and a resistance mutation, none of the 4 approved drugs had potent activity against both classes of resistance mutations. In contrast, THE-630 potently inhibited ATP binding pocket mutants (V654A and T670I) and activation loop mutants (D816G/H, D820A/G, N822K, Y823D, A829P), with IC50s all below 25 nM. THE-630 also had potent activity against V654A and D816H in the context of an Ex9 primary mutation (IC50s 10 and 33 nM). In vivo, THE-630 strongly inhibited tumor growth (by 86%) in a model containing the most common ATP binding pocket mutant (V654A) as a secondary mutation, while ripretinib achieved only modest inhibition (26%). THE-630 was also highly active in models expressing secondary activation loop mutants, regressing tumors containing N822K by 88% (compared to 25% tumor growth inhibition by sunitinib) and regressing tumors containing D820A by 59% (compared to 1% tumor regression by ripretinib). Conclusions: We have identified a next-generation pan-KIT inhibitor that has potent activity against all major classes of activating and resistance mutations observed in KIT-mutant GIST patients. A phase 1 clinical trial of THE-630 is planned to begin in 2021.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
THE-630 THE-630 12 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
THE-630 THE 630|THE630 KIT Inhibitor 55 THE-630 is a pan-KIT inhibitor, which may lead to reduced cell proliferation and tumor regression (Cancer Res 2021;81(13_Suppl):Abstract nr 1292).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT exon 11 del KIT Y823D Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT Y823D in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT D816H Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT D816H in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 9 ins KIT D816G Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 9 insertion and KIT D816G in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT N822K Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT N822K in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT V654A Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT V654A in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT T670I Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT T670I in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT D816G Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT D816G in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del gastrointestinal stromal tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited cell viability and KIT signaling in a gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT D820A Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT D820A in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT A829P Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT A829P in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 11 del KIT D820G Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 11 deletion and KIT D820G in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...
KIT exon 9 ins KIT V654A Advanced Solid Tumor predicted - sensitive THE-630 Preclinical - Cell culture Actionable In a preclinical study, THE-630 treatment inhibited growth of cells co-expressing a KIT exon 9 insertion and KIT V654A in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292). detail...